中国中医药信息杂志2015，Vol.22Issue(11)：31-35,5.DOI:10.3969/j.issn.1005-5304.2015.11.009
古方治疗中晚期原发性肝癌随机对照试验Meta分析
Ancient Classical Prescriptions Treating Middle and Advanced Primary Liver Cancer:A Meta-analysis of Randomized Controlled Trials
摘要
Abstract
Objective To evaluate the efficacy of ancient classical prescriptions treating middle and advanced primary liver cancer.Methods Articles were searched from Pubmed, Embase, SCI, Cochrane Liarary and CNKI, VIP, WanFang Data, CBM databases. Randomized controlled trials about ancient classical prescriptions treating advanced primary liver cancer were collected. Results 17 studies were included, a total of 994 patients. The recent efficiency of ancient classical prescription combined with symptomatic therapy increased by 28% compared with single supportive and symptomatic therapy;the stable rate of life quality increased by 23%;the efficiency of TCM syndrome increased by 29%;the survival rates of 3 months, 6 months and 1 year increased by 16%, 36.7% and 58.5% respectively;the life quality score of later increased by 6.29 on average. Conclusion Ancient classical prescription combined with supportive and symptomatic therapy in advanced primary liver cancers is superior to single supportive and symptomatic therapy on recent efficiency, survival rate (3 months/6 months/1 year), quality of life and TCM syndrome. The conclusion of this study needs randomized controlled trials with larger samples, multicenter and high quality for further verification.关键词
古方/支持对症疗法/中晚期原发性肝癌/随机对照试验/Meta分析Key words
ancient classical prescriptions/symptomatic therapy/middle and advanced primary liver cancer/randomized controlled trial/Meta-analysis分类
医药卫生引用本文复制引用
赵秀秀,李博,曲骞,郝腾,刘维丽,吴煜..古方治疗中晚期原发性肝癌随机对照试验Meta分析[J].中国中医药信息杂志,2015,22(11):31-35,5.基金项目
国家"重大新药创制"创新药物研究开发技术平台建设(2012ZX09303-010-002) （2012ZX09303-010-002）
国家自然科学基金青年基金(81303151) （81303151）
